Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function

Shantsila, Eduard; Tapp, Luke; Lip, Gregory Y.H.

doi:10.1016/j.ijcard.2015.03.105

Cited by 9 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the role of sFLC in determining cardiovascular disease, in particular ischemic heart disease and HF, has been investigated by several studies. Bellary et al suggested their possible role for the stratification of cardiovascular risk in patients with or without type 2 diabetes mellitus [62]; Shantsila et al proposed sFLC as a predictive marker of mortality in patients with acute HF and acute coronary syndromes [63,64]. Serum FLC increase has already been proved to correlate with an increased risk of mortality.…”

Section: Serum Free Light Chains (Sflc)mentioning

confidence: 99%

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective

Biasucci

Maino

Grimaldi

et al. 2021

JCM

View full text Add to dashboard Cite

Heart failure (HF) is a complex clinical syndrome with a huge social burden in terms of cost, morbidity, and mortality. Brain natriuretic peptide (BNP) appears to be the gold standard in supporting the daily clinical management of patients with HF. Novel biomarkers may supplement BNP to improve the understanding of this complex disease process and, possibly, to personalize care for the different phenotypes, in order to ameliorate prognosis. In this review, we will examine some of the most promising novel biomarkers in HF. Inflammation plays a pivotal role in the genesis and progression of HF and, therefore, several candidate molecules have been investigated in recent years for diagnosis, prognosis, and therapy monitoring. Noncoding RNAs are attractive as biomarkers and their potential clinical applications may be feasible in the era of personalized medicine. Given the complex pathophysiology of HF, it is reasonable to expect that the future of biomarkers lies in the application of precision medicine, through wider testing panels and “omics” technologies, to further improve HF care delivery.

show abstract

Section: Serum Free Light Chains (Sflc)mentioning

confidence: 99%

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective

Biasucci

Maino

Grimaldi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Inflammation is a central process in the development and progress of both chronic and acute diseases. In the spectrum of cardiology, inflammation is one of the major forces in atherosclerosis [1], in acute coronary syndromes [2, 3], and heart failure [4–7]. In the aging process, signs of both increasing inflammatory activity [8], and oxidative stress are commonly observed [9].…”

Section: Introductionmentioning

confidence: 99%

Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: a subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK

et al. 2019

View full text Add to dashboard Cite

BackgroundInflammation is central to the pathogenesis of many diseases. Supplementation with selenium and coenzyme Q10 has been shown to reduce cardiovascular mortality, and increase cardiac function in elderly persons with a low intake of selenium. There are indications that one of the mechanisms of this positive effect is a decrease in inflammation.MethodsOsteopontin, osteoprotegerin, sTNF receptor 1, sTNF receptor 2 and the tumor necrosis factor-like weak inducer of apoptosis called TWEAK, were determined in plasma after 6 months and 42 months in 219 community-living elderly persons, of whom 119 received supplements of selenium (200 μg/day) and coenzyme Q10 (200 mg/day), and 101 received a placebo. Repeated measures of variance were used to evaluate the levels, and the results were validated through ANCOVA analyses with adjustments for important covariates.ResultsSignificantly lower concentrations of four of the five biomarkers for inflammation were observed as a result of the intervention with the supplements. Only TWEAK did not show significant differences.ConclusionIn this sub-analysis of the intervention with selenium and coenzyme Q10 or placebo in an elderly community-living population, biomarkers for inflammation were evaluated. A significantly lower concentration in four of the five biomarkers tested could be demonstrated as a result of the supplementation, indicating a robust effect on the inflammatory system. The decrease in inflammation could be one of the mechanisms behind the positive clinical results on reduced cardiovascular morbidity and mortality reported earlier as a result of the intervention. The study is small and should be regarded as hypothesis-generating, but nonetheless adds important data about mechanisms presently known to increase the risk of clinical effects such as reduced cardiovascular mortality, increased cardiac function and better health-related quality of life scoring, as previously demonstrated in the active treatment group .Trial registrationThe intervention study was registered at Clinicaltrials.gov, and has the identifier NCT01443780 and registered on 09/30/2011.

show abstract

“…Inflammation is part of the atherosclerotic process in the body[ 1 ], but also in other processes, including different disease states such as e.g. cardiometabolic syndrome, acute coronary syndromes [ 2 , 3 ], heart failure with preserved ejection fraction [ 4 , 5 ] as well as heart failure with reduced ejection fraction [ 6 , 7 ] and also in aortic stenosis [ 8 ] and rheumatoid inflammations that may predispose a patient to cardiovascular disease. Aging itself is also associated with an increased inflammatory response [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial

et al. 2015

View full text Add to dashboard Cite

Background/ObjectivesInflammation and oxidative stress are central in many disease states. The major anti-oxidative enzymes contain selenium. The selenium intake in Europe is low, and supplementation with selenium and coenzyme Q10, important anti-oxidants, was evaluated in a previous study. The aim of this study was to evaluate response on the inflammatory biomarkers C-reactive protein, and sP-selectin, and their possible impact on cardiovascular mortality.Subjects/Methods437 elderly individuals were included in the study. Clinical examination, echocardiography, electrocardiography and blood samples were drawn. The intervention time was 48 months, and median follow-up was 5.2 years. The effects on inflammation/atherosclerosis were evaluated through analyses of CRP and sP-selectin. Evaluations of the effect of the intervention was performed using repeated measures of variance. All mortality was registered, and endpoints of mortality were assessed by Kaplan-Meier plots.ResultsThe placebo group showed a CRP level of 4.8 ng/mL at the start, and 5.1 ng/mL at the study end. The active supplementation group showed a CRP level of 4.1 ng/mL at the start, and 2.1 ng/mL at the study end. SP-selectin exhibited a level of 56.6 mg/mL at the start in the placebo group and 72.3 mg/mL at the study end, and in the active group the corresponding figures were 55.9 mg/mL and 58.0 mg/mL. A significantly smaller increase was demonstrated through repeated measurements of the two biomarkers in those on active supplementation. Active supplementation showed an effect on the CRP and sP-selectin levels, irrespective of the biomarker levels. Reduced cardiovascular mortality was demonstrated in both those with high and low levels of CRP and sP-selectin in the active supplementation group.ConclusionCRP and sP-selectin showed significant changes reflecting effects on inflammation and atherosclerosis in those given selenium and coenzyme Q10 combined. A reduced cardiovascular mortality could be demonstrated in the active group, irrespective of biomarker level. This result should be regarded as hypothesis-generating, and it is hoped it will stimulate more research in the area.

show abstract

Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function

Abstract: cFLC levels increase during STEMI with peak values on day 7 after presentation and predict the need for future PCI.

Cited by 9 publications

References 36 publications

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective

Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective

Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: a subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK

Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial

Contact Info

Product

Resources

About